- In January 2025, the European Medicines Agency (EMA) recommended the approval of the Bluevac-3 and Syvazul BTV 3 vaccines to protect sheep from bluetongue disease. Bluevac-3 is also approved for use in cattle. Bluetongue disease is caused by the bluetongue virus, which has several different serotypes. These vaccines have been shown to protect against the newly emerged serotype-3 bluetongue virus (BTV3), responsible for recent outbreaks in Europe. They offer protection against this strain, which current EU-approved vaccines provide limited defense against.
- In September 2024, Boehringer Ingelheim announced its acquisition of Saiba Animal Health AG, a company dedicated to developing innovative therapeutic solutions for chronic diseases in pets. This acquisition enhances Boehringer Ingelheim’s research and development (R&D) pipeline, particularly in the rapidly expanding pet therapeutics market. As the life expectancy of pets continues to rise, the demand for effective treatments for debilitating diseases is also growing.
- In March 2024, Merck Animal Health announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBILIS MULTRIVA RT+IBm+ND+Gm+REOm+EDS vaccine. This vaccine, which is administered intramuscularly in chickens, provides protection against diseases caused by avian metapneumovirus. With this positive opinion, the NOBILIS MULTRIVA vaccine is now one step closer to becoming the first 9-valent inactivated viral vaccine in Europe.
- In February 2024, Merck Animal Health announced it had reached a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for USD 1.3 billion in cash. The acquisition includes an innovative portfolio of medicines, vaccines, nutritionals, and supplements for aquatic species, along with two related aqua manufacturing facilities in Canada and Vietnam, as well as a research facility in Chile.
- In January 2021, Zoetis expanded its range of recombinant vector vaccines with the introduction of Poulvac Procerta HVT-IBD. This vaccine offers early protection against the current infectious bursal disease (IBD) viruses affecting U.S. broilers. Poulvac Procerta HVT-IBD is an essential tool for managing IBD, providing a high level of protection, including early defense against IBD viruses, such as the dominant AL2 variant.
Frequently Asked Questions
Companies such as Boehringer Ingelheim International GmbH (Germany), Biogénesis Bagó S.A. (Argentina), BIO-MED (India), Ceva (France) and Dechra Pharmaceuticals Limited (U.K.) are the major companies in the inactivated veterinary vaccine market.
In January 2025, the European Medicines Agency (EMA) recommended the approval of the Bluevac-3 and Syvazul BTV 3 vaccines to protect sheep from bluetongue disease. In January 2021, Zoetis expanded its range of recombinant vector vaccines with the introduction of Poulvac Procerta HVT-IBD.
The countries covered in the inactivated veterinary vaccine market are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
